Brought to you by 
Alexion buys Wilson Therapeutics
25 Aug 2020
Executive Summary
Alexion Pharmaceuticals Inc. offered SEK232 ($27.84) per share to acquire Wilson Therapeutics AB, a Swedish biotech developing its sole candidate for the rare genetic condition Wilson disease. The deal is valued at SEK6.56bn (equity value SEK7.1bn on a fully diluted basis), and the share price represents a 62% premium to Wilson’s ten-day pre-announcement market average.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Intra-Biotech Deal
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Alexion buys Wilson Therapeutics
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice